How is semax dosed and mixed?
500 mcg of Semax from a 10 mg vial mixed with 2 mL is 10 units on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water | 3 mL of water |
|---|---|---|---|
| 10 mg75% set up11 | 10 mg/mL: 250 mcg is 2.5 units, 300 mcg is 3 units, 400 mcg is 4 units, 500 mcg is 5 units | 5 mg/mL: 250 mcg is 5 units, 300 mcg is 6 units, 400 mcg is 8 units, 500 mcg is 10 units | 3.333 mg/mL: 250 mcg is 7.5 units, 300 mcg is 9 units, 400 mcg is 12 units, 500 mcg is 15 units |
| 5 mg15% set up11 | 5 mg/mL: 250 mcg is 5 units, 300 mcg is 6 units, 400 mcg is 8 units, 500 mcg is 10 units | 2.5 mg/mL: 250 mcg is 10 units, 300 mcg is 12 units, 400 mcg is 16 units, 500 mcg is 20 units | 1.667 mg/mL: 250 mcg is 15 units, 300 mcg is 18 units, 400 mcg is 24 units, 500 mcg is 30 units |
Most often logged by Milligram users: 500 mcg, 36% logged.11
Vial strengths, water and syringe marks
Of the people who logged semax, 75% set up a 10 mg vial and 15% a 5 mg vial.11 A 10 mg vial with 2 mL was set up by 45%, and with 1 mL or 3 mL by 13% each.11
On the water, FDA's briefing cites semax free base as soluble in water up to 2 mg/mL and about 10 mg/mL in phosphate-buffered saline.2 Both logged 10 mg mixes, 2 mL (45%) and 1 mL (13%), come out above that 2 mg/mL.211 For semax acetate, FDA says one withdrawn nominator's certificate of analysis calls it soluble in water, but neither nomination held water solubility data.2
500 mcg of Semax from a 10 mg vial mixed with 2 mL is 10 units on a U-100 syringe.
45% set up 10 mg + 2 mL11
500 mcg of Semax from a 10 mg vial mixed with 2 mL is 10 units on a U-100 syringe. Set to 500 mcg, the dose most often logged by Milligram users (36%).11
Doses and schedules
The Russian label for Semax 0.1% nasal drops puts, in micrograms, 50 in one drop and gives no more than 2 to 3 drops per nostril at a time, with larger doses given in several applications 10 to 15 minutes apart.12 In days and micrograms, it extends the course to 14 if needed, gives a whole-day total of 500 to 5000 (7 to 70 per kg), and its 1% drops hold 500 in one drop.12 In micrograms, the whole-day total is 600 to 900 for optic nerve disease and 200 to 400 for children with minimal brain dysfunction, and for the 1% drops 6000 to 12000 in moderate and 12000 to 20000 in severe stroke.12
FDA counts the human exposure it reviewed as 33-47 healthy adults, 69 adults with medical conditions and 451 children with depression or tics/Tourette syndrome, all by the intranasal route.2
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Kaplan 19962 | Intranasal 1 mg daily, or 0.25 mg once2 | 19 healthy men2 | 2 days, or once2 |
| Koroleva 19962 | Intranasal 0.5 mg/kg once2 | 37 adults with pain2 | Once |
| Ivanikov 200223 | 1% solution intranasal, 2-4 drops per nostril three times a day, plus basic therapy against basic therapy alone2 | 32 adults with refractory peptic ulcer23 | 10 days; ulcer healing on day 14 in 89.5% against 30.8% in controls3 |
| Gusev 19974 | Daily doses the report calls effective: 12 mg (moderate stroke), 18 mg (severe), with intensive therapy, route not stated4 | 30 patients, 80 controls on conventional therapy4 | Courses of 5 and 10 days4 |
| Gusev 20185 | Standard regimen 6000 mcg/day, route not stated, semax subgroups against no-semax subgroups5 | 110 patients after stroke, in early and late rehabilitation groups5 | 2 courses of 10 days, 20-day interval5 |
| Serdiuk 20076 | 1% semax intranasal, 12 mg daily, open-label6 | 27 patients, motor neuron disease6 | 2 courses of 10 days, 2-week break6 |
| Lebedeva 201872 | Intranasal 1% semax, 1.2 mg per FDA, against placebo72 | Healthy volunteers: 14 on semax, 10 on placebo7 | Scans before and 5 and 20 minutes after dosing7 |
| Dontsova 20158 | 0.1% semax intranasal, 600 mg/day as printed, plus conventional therapy8 | 60 patients with psoriasis, against 58 on conventional therapy8 | 10 days8 |
Of the people who logged semax, 71% logged doses in mcg and 26% in mg.11 A dose of 500 mcg was set up by 36% of people, the largest share, and doses of 250, 300 and 400 mcg by 10% each.11
Nasal or injected
Of the people who logged semax, 72% logged under the skin, 21% nasal and 7% muscle.11 The Russian label describes intranasal use with a dropper stopper.1 FDA found no study of semax given by subcutaneous injection and could assess safety only for the intranasal route.2 FDA also found no pharmacokinetic study of semax in humans by any route.2 No label or trial found gives a dose or an injection site for an injected route. A 1999 study by Alekseeva and colleagues in 73 patients with posthypoxic encephalopathy describes semax by injection but gives no dose, route or site.9
Storage
The Russian label says to store Semax nasal drops protected from light at not above 10 °C, not frozen.1 The label gives storage only for the finished drops, not for a mixed powder.
FDA's briefing, citing references, reports lyophilized semax free base stable for 4 years at -20°C closed tightly, and the reconstituted solution kept at +4°C for up to 2-7 days.2 Cayman Chemical's research sheet does not recommend storing the aqueous solution for more than one day.10
Frequently asked questions
Is semax approved by FDA?
FDA says neither semax free base nor semax acetate is a component of an FDA-approved drug.2
Is semax in a registered trial?
ClinicalTrials.gov searches for semax returned no registered study, and a search of the EU Clinical Trials Register did not return a page.
How the logged figures are counted
Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.
References
- RLS (Russian drug encyclopedia), reproducing the registered instruction. Semax nasal drops 0.1% and 1%: instructions for use (RLS drug encyclopedia, based on the manufacturer's official instruction approved 2008; in Russian). 2008. rlsnet.ru
- US Food and Drug Administration. FDA briefing document: evaluation of semax-related bulk drug substances for the 503A bulk drug substances list (Pharmacy Compounding Advisory Committee, 23-24 July 2026). 2026. fda.gov
- Bulletin of Experimental Biology and Medicine (PubMed record). Therapy of peptic ulcer with semax peptide (Ivanikov and colleagues). 2002. pubmed.ncbi.nlm.nih.gov
- Zh Nevrol Psikhiatr Im S S Korsakova (PubMed record). Effectiveness of semax in acute period of hemispheric ischemic stroke (Gusev and colleagues). 1997. pubmed.ncbi.nlm.nih.gov
- Zh Nevrol Psikhiatr Im S S Korsakova (PubMed record). The efficacy of semax in the treatment of patients at different stages of ischemic stroke (Gusev and colleagues). 2018. pubmed.ncbi.nlm.nih.gov
- Zh Nevrol Psikhiatr Im S S Korsakova (PubMed record). Chronic partial denervation and quality of life in patients with motor neuron disease treated with semax (Serdiuk and colleagues). 2007. pubmed.ncbi.nlm.nih.gov
- Bulletin of Experimental Biology and Medicine (PubMed record). Effects of Semax on the Default Mode Network of the Brain (Lebedeva and colleagues). 2018. pubmed.ncbi.nlm.nih.gov
- Eksperimentalnaia i Klinicheskaia Farmakologiia (PubMed record). Possible drug correction of lipid metabolism disturbances associated with metabolic syndrome in patients with psoriasis (Dontsova). 2015. pubmed.ncbi.nlm.nih.gov
- Anesteziologiia i Reanimatologiia (PubMed record). Use of semax at a follow-up of patients with posthypoxic encephalopathy (Alekseeva and colleagues). 1999. pubmed.ncbi.nlm.nih.gov
- Cayman Chemical. Semax, Product Information, Item No. 27719. 2023. cdn.caymanchem.com
- Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted